Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia

被引:33
作者
Nielsen, Stine Nygaard [1 ]
Grell, Kathrine [1 ,2 ]
Nersting, Jacob [1 ]
Frandsen, Thomas Leth [1 ]
Hjalgrim, Lisa Lyngsie [1 ]
Schmiegelow, Kjeld [1 ,3 ]
机构
[1] Rigshosp, Dept Pediat & Adolescent Med, Univ Hosp, JMC 4072,Blegdamsvej 9, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, Sect Biostat, Dept Publ Hlth, Copenhagen, Denmark
[3] Univ Copenhagen, Inst Clin Med, Copenhagen, Denmark
关键词
ALL; Myelosuppression; Maintenance therapy; 6-Mercaptopurine; Methotrexate; RED-BLOOD-CELLS; THIOPURINE METHYLTRANSFERASE; STANDARD RISK; 6-THIOGUANINE NUCLEOTIDES; PROGNOSTIC IMPORTANCE; CHILDREN; CHEMOTHERAPY; DNA; TOXICITY; TRIALS;
D O I
10.1007/s00280-016-3151-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Normal white blood cell counts (WBC) are unknown in children with acute lymphoblastic leukemia (ALL). Accordingly, 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy is adjusted by a common WBC target of 1.5-3.0 x 10(9)/L. Consequently, the absolute degree of myelosuppression is unknown for the individual child and we wanted to evaluate this. A median of 22 (range 8-27) 6MP/MTX metabolite samples and 100 (range 25-130) blood counts during therapy and 10 (range 2-15) off therapy were collected in 50 children with ALL. Differences between off-therapy and on-therapy WBCs [including absolute neutrophil (ANC) and lymphocyte counts (ALC)] were used to retrospectively approximate the absolute myelosuppression (="delta-") and association with age, sex and 6MP/MTX doses explored. We applied linear mixed models to estimate on-therapy counts by 6MP/MTX metabolites: DNA-incorporated thioguanine nucleotides (DNA-TGN), erythrocyte thioguanine nucleotides (ery-TGN), erythrocyte-methylated 6MP metabolites (ery-MeMP) and erythrocyte MTX polyglutamates with 2-6 glutamate residues (ery-MTXpg(2-6)). On-therapy WBC was correlated with ANC and ALC (r (s) = 0.84 and r (s) = 0.33, p values < 0.001), whereas ANC was weakly correlated with ALC (r (s) = -0.11, p < 0.001), and neither significantly correlated with age. Off-therapy ALC, but not ANC, was strongly correlated with age (r (s) = -0.68 and -0.18, p < 0.001 and p = 0.22). Delta-ALC decreased with increasing age (r (s) = -0.69, p < 0.001). Incorporation of DNA-TGN was positively associated with ery-TGN (p < 0.001), ery-MeMP (p < 0.001) and ery-MTXpg(2-6) (p = 0.047). On-therapy ALC decreased with increasing DNA-TGN level (p < 0.001, model adjusted for off-therapy ALC), whereas on-therapy ANC could not be modeled reliably. Measurements of 6MP/MTX metabolites could supplement blood counts in assessing therapy intensity, but require prospective validation.
引用
收藏
页码:983 / 994
页数:12
相关论文
共 42 条
[1]   Population-based pediatric reference intervals for hematology, iron and transferrin [J].
Aldrimer, Mattias ;
Ridefelt, Peter ;
Rodoo, Peo ;
Niklasson, Frank ;
Gustafsson, Jan ;
Hellberg, Dan .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2013, 73 (03) :253-261
[2]   The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005 [J].
M Aricó ;
A Baruchel ;
Y Bertrand ;
A Biondi ;
V Conter ;
T Eden ;
H Gadner ;
P Gaynon ;
K Horibe ;
S P Hunger ;
G Janka-Schaub ;
G Masera ;
J Nachman ;
R Pieters ;
M Schrappe ;
K Schmiegelow ;
M G Valsecchi ;
C-H Pui .
Leukemia, 2005, 19 (7) :1145-1152
[3]   POLYGLUTAMATION OF METHOTREXATE - IS METHOTREXATE A PRODRUG [J].
CHABNER, BA ;
ALLEGRA, CJ ;
CURT, GA ;
CLENDENINN, NJ ;
BARAM, J ;
KOIZUMI, S ;
DRAKE, JC ;
JOLIVET, J .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (03) :907-912
[4]   Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X [J].
Chessells, JM ;
Harrison, G ;
Lilleyman, JS ;
Bailey, CC ;
Richards, SM .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) :945-951
[5]   Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy [J].
de Beaumais, Tiphaine Adam ;
Fakhoury, May ;
Medard, Yves ;
Azougagh, Said ;
Zhang, Daolun ;
Yakouben, Karima ;
Jacqz-Aigrain, Evelyne .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (04) :575-584
[6]   Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method [J].
den Boer, E. ;
Meesters, R. J. W. ;
van Zelst, B. D. ;
Luider, T. M. ;
Hazes, J. M. W. ;
Heil, S. G. ;
de Jonge, R. .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (05) :1673-1681
[7]   PROGNOSTIC IMPORTANCE OF MYELOSUPPRESSION DURING MAINTENANCE TREATMENT OF LYMPHOBLASTIC-LEUKEMIA [J].
DOLAN, G ;
LILLEYMAN, JS ;
RICHARDS, SM .
ARCHIVES OF DISEASE IN CHILDHOOD, 1989, 64 (09) :1231-1234
[8]   Incorporation of 6-Thioguanine Nucleotides into DNA During Maintenance Therapy of Childhood Acute Lymphoblastic LeukemiaThe Influence of Thiopurine Methyltransferase Genotypes [J].
Ebbesen, Maria S. ;
Nersting, Jacob ;
Jacobsen, Jack H. ;
Frandsen, Thomas L. ;
Vettenranta, Kim ;
Abramsson, Jonas ;
Wesenberg, Finn ;
Schmiegelow, Kjeld .
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (06) :670-674
[9]   Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection [J].
El-Chennawi, Farha A. ;
Al-Tonbary, Youssef A. ;
Mossad, Youssef M. ;
Ahmed, Mona A. .
HEMATOLOGY, 2008, 13 (04) :203-209
[10]   Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients [J].
Eyrich, Matthias ;
Wiegering, Verena ;
Lim, Annick ;
Schrauder, Andre ;
Winkler, Beate ;
Schlegel, Paul G. .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (03) :360-370